ONC -130320-1 7/2013 Welcome to a scientific education for young urologists on Castrate-Resistant Prostate Cancer Copenhagen 22-23 November Bella Sky Comwell, Copenhagen Per-Anders Abrahamsson Jack Schalken Jan-Erik Damber Karol Axcrona Peter Iversen Mika Matikainen Sten Nilsson Henriette Lindberg Anders Angelsen Ulf Persson Professor, MD, PhD Department of Urology Skåne University Hospital Sweden Vik ihop på mitten efter den prickade linjen med denna sidan utåt och tejpa ihop. Professor, MD, PhD Department of Urology Sahlgrenska University Hospital and Academy Gothenburg, Sweden Professor, MD Department of Urology Rigshospitalet, Copenhagen Denmark Frankeras ej Astellas Pharma AB betalar portot Professor, MD, PhD Department of Oncology Karolinska Institutet Stockholm, Sweden Professor, MD, PhD Dept of Cancer Research and Molecular Medicine Dept of Urological Surgery St. Olavs Hospital Trondheim, Norway Astellas Pharma AB SVARSPOST Kundnummer 20 46 43 37 208 00 Malmö Astellas Pharma AB | Box 21046 | 200 21 Malmö Telefon 040-650 15 00 | Fax 040-650 15 01 [email protected] | www.astellas.se Professor of Experimental Urology, PhD Research Director Urology Radboud University, Nijmegen, Medical Center The Netherlands Consultant in Urology, MD, PhD Department of Urology The Norwegian Radium Hospital Oslo University Hospital Oslo, Norway Adjunct Professor, MD, PhD Department of Urology Helsinki University Central Hospital Helsinki, Finland MD, PhD Department of Oncology Herlev Hospital, University of Copenhagen Herlev, Denmark Professor in Health Economics at Lund University CEO of IHE, The Swedish Institute for Health Economics Lund, Sweden 22 November Chairman of day 1 Per-Anders Abrahamsson 09.00-9.30 Introduction Faculty presentation Background/rationale, purpose, objectives Definition of CRPC Per-Anders Abrahamsson 09.30-10.15 Biological aspects in prostate cancer progression Karol Axcrona 10.15-10.45 Coffee break 10.45-11.45 Targeting the androgen receptor in CRPC Overview of CRPC Jack Schalken We are in the middle of an exciting phase in the development of treatment options for patients suffering from metastatic castration-resistant prostate cancer. Take this opportunity to update and advance your knowledge of the management of patients suffering from castration-resistant prostate cancer! SVARSKORT NORDIC CRPC CAMP, Copenhagen 22-23 november 2013 Welcome to a Scientific Education on castration-resistant prostate cancer (CRPC) Födelsedatum:_______________________________________________________________________ Copenhagen, 22-23 November 2013 Klinik:_______________________________________________________________________________ Tremendous advancements are being made in the treatments available for patients suffering from metastatic castration-resistant prostate cancer, and principles of modern treatments are being introduced also for patients suffering from CRPC. Adress:______________________________________________________________________________ Patients with advanced prostate cancer can look forward, with anticipation and confidence, to a variety of new treatment options and better methods for determining which of the tumours identified will require treatment in the coming years. Telefonnr./Mobilnr:____________________________________________________________________ CRPC camp aims to provide attendees with the latest update and advance their knowledge of all aspects of the management of patients with CRPC. Önskemål om avreseflygplats:__________________________________________________________ 11.45-12.45Lunch 12.45-13.35 Cancer treatment and health economics – basics and insights Ulf Persson 13.35-14.35 Clinical presentations of CRPC Mika Matikainen 14.35-15.00 Coffee break 15.00-16.00 E pidemiology of CRPC Jan-Erik Damber 16.00-16.15 Short break 16.15-17.30 Update on current and new treatment modalities Peter Iversen 17.30-17.45 Closure Per-Anders Abrahamsson A scientific education on Castrate-Resistant Prostate Cancer (CRPC) Optional arrival with dinner on the evening of november 21. Changes in programme may occur. 19.30 23 November Bus departure to restaurant The urology department is the natural basis of the treatment of urology patients. As the condition progresses, it is imperative that multidisciplinary collaboration is optimal. 08.45-09.00 Introduction day 2 Multidisciplinarity – why? Peter Iversen 09.00-10.00 Multidisciplinary teamwork Update on other modalities Sten Nilsson & Henriette Lindberg Coffee break 10.30-11.30 Management of complications Anders Angelsen 12.15-13.00Lunch PL P www.CR C camp.com : young USER N A ME : urologists PA SSWORD 13.00-13.50 Sequencing treatments Overview of new knowledge. How to treat. Per-Anders Abrahamsson 13.50-14.50 National guidelines for CRPC Jan-Erik Damber, Peter Iversen, Anders Angelsen, Mika Matikainen 14.50-15.00 Postnr.:_____________________ Ort:_____________________________________________________ E-post för registrering:________________________________________________________________ Transport till och från flygplatsen, ange adress:___________________________________________ Övriga upplysningar (Allergi etc.): _______________________________________________________ Arbetsgivaren betalar deltagaravgiften (preliminärt SEK 2 900:- ex moms). Deltagaravgiften motsvarar 50% av kostnaden för resa, hotell inkl. frukost samt gemensamma måltider. Arbetsgivaren önskar stå för mer än 50 % av kostnaderna (ange hur mycket): Per-Anders Abrahamsson Professor, MD, PhD Department of Urology Skåne University Hospital Malmö, Sweden Peter Iversen Professor, MD Department of Urology Rigshospitalet Copenhagen, Denmark Closure Peter Iversen Enligt avtal mellan Läkemedelsindustriföreningen och SKL ska deltagande godkännas av huvudmannen. En kopia för kännedom skickas även till den lokala Läkemedelskommitén. Information om överenskommelse om samverkansformer mellan läkemedelsföretag och medarbetare i den offentliga hälso- och sjukvården finns på www.lif.se. Jan-Erik Damber Professor, MD, PhD Department of Urology Sahlgrenska University Hospital and Academy Gothenburg, Sweden Karol Axcrona Consultant, MD, PhD Department of Urology Oslo universitetssykehus The Norwegian Radium Hospital Oslo, Norway 11.30-12.15 Multidisciplinary teamwork Sten Nilsson, Henriette Lindberg & Anders Angelsen E A SE V ISIT Sjukhus:_____________________________________________________________________________ Chairman of day 2 Peter Iversen 08.30-08.45 Recap of day 1 Per-Anders Abrahamsson 10.00-10.30 In addition to lectures, emphasis will be placed on the exchange of experience and sharing-best-practice between participants and some of the top opinion leaders within the field of therapy. Namn (som i pass):___________________________________________________________________ Huvudmans-/verksamhetsansvarigs godkännande: Underskrift huvudman/verksamhetsansvarig Mika Matikainen Adjunct Professor, MD, PhD Department of Urology Helsinki University Central Hospital. Helsinki, Finland Sten Nilsson Professor, MD, PhD Department of Oncology. Karolinska Institutet Stockholm, Sweden Henriette Lindberg MD, PhD Department of Oncology Herlev Hospital, University of Copenhagen Herlev, Denmark Namnförtydligande Anders Angelsen Professor, MD, PhD Dept of Cancer Research and Molecular Medicine Dept of Urological Surgery St. Olavs Hospital. Trondheim, Norway Ort/datum Astellas Pharma AB, Box 21046, 200 21 Malmö. Telefon: 040-650 15 00. Fax: 040-650 15 01. [email protected]. www.astellas.se.
© Copyright 2024